| Date Filed | Type | Description |
| 08/18/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.785, valued at
$1.9M
|
|
| 08/18/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $2.785, valued at
$835.5k
|
|
| 08/18/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $2.785, valued at
$69.6k
|
|
| 08/18/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.785, valued at
$380.2k
|
|
| 08/07/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 150,000 options to buy
@ $2.75, valued at
$412.5k
|
|
| 08/07/2023 |
3
| Frankenfield Christopher James (COO) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 04/03/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 55,000 options to buy
@ $3.17, valued at
$174.4k
|
|
| 04/03/2023 |
3
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 01/04/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 350,000 options to buy
@ $2.69, valued at
$941.5k
|
|
| 01/04/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.69, valued at
$367.2k
|
|
| 01/04/2023 |
4
| English Edward C (PRINCIPAL ACCOUNTING OFFICER) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 24,000 options to buy
@ $2.69, valued at
$64.6k
|
|
| 11/16/2022 |
3
| English Edward C (Principal Accounting Officer) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 09/16/2022 |
3
| Heyman Tomas J. (Director) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 09/16/2022 |
4
| Heyman Tomas J. (Director) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 26,400 options to buy
@ $3.15, valued at
$83.2k
|
|
| 06/23/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/24/2022 |
4
| Giovine Salvatore (CFO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 49,500 options to buy
@ $12.66, valued at
$626.7k
|
|
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2022 |
4
| Xu Yuan (Director) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 26,400 options to buy
@ $15.92, valued at
$420.3k
|
|
| 01/06/2022 |
3
| Xu Yuan (Director) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 01/04/2022 |
4/A
| Russo Rene (CEO AND PRESIDENT) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $13.83, valued at
$1.4M
|
|
| 12/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/05/2021 |
3
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 11/03/2021 |
4/A
| SV7 Impact Medicine Fund LP (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 998,544 shares
@ $0
Converted 998,544 shares
@ $0
Converted 302,588 shares
@ $0
Converted 302,588 shares
@ $0
Bought 312,500 shares
@ $16, valued at
$5M
Bought 312,500 shares
@ $16, valued at
$5M
Converted 9,486,166 convertible preferred
@ $0
Converted 9,486,166 convertible preferred
@ $0
Converted 2,874,595 convertible preferred
@ $0
Converted 2,874,595 convertible preferred
@ $0 |
|
| 10/28/2021 |
4
| Flynn James E (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 756,472 shares
@ $0
Bought 387,500 shares
@ $16, valued at
$6.2M
Converted 7,186,489 preferred shares
@ $0 |
|
|